Why the study?
Does anti-MCP-1 monoclonal neutralizing antibody improve myocardial fibrosis and diastolic dysfunction in Wistar rats with suprarenal aortic constriction?
Population
Wistar rats with suprarenal aortic constriction (pressure-overloaded hearts)
Design
Preclinical
Follow-up
28 days
Authors
Loading...
Does not support clinical use of anti-MCP-1 antibodies; extends preclinical evidence but leaves human translation open.
Does anti-MCP-1 monoclonal neutralizing antibody improve myocardial fibrosis and diastolic dysfunction in Wistar rats with suprarenal aortic constriction?
Inhibition of MCP-1-mediated inflammation attenuates myocardial fibrosis and improves diastolic dysfunction in a rat model of pressure overload.
Kuwahara et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: